Page last updated: 2024-12-07

cryptolepine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cryptolepine is a natural alkaloid extracted from the plant *Cryptolepis sanguinolenta*. It has been studied for its potential pharmacological properties, including anti-cancer, anti-malarial, anti-inflammatory, and anti-bacterial activities. The compound is known to interact with DNA and inhibit the growth of various cancer cell lines. Its synthesis can be achieved through different methods, including extraction from plant sources or chemical synthesis. Cryptolepine's complex structure and potential for therapeutic applications make it a subject of ongoing research.'

cryptolepine: fused indole-quinoline; structure in first source; from CRYPTOLEPIS sanguinolenta [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cryptolepine : An organic heterotetracyclic compound that is 5H-indolo[3,2-b]quinoline in which the hydrogen at position N-5 is replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CryptolepisgenusA plant genus of the family ASCLEPIADACEAE. Members contain the alkaloids quindoline, CSA-3, cryptolepine, and neocryptolepine.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]
Cryptolepis sanguinolentaspecies[no description available]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]

Cross-References

ID SourceID
PubMed CID82143
CHEMBL ID119096
CHEBI ID3930
SCHEMBL ID542771
MeSH IDM0081885

Synonyms (21)

Synonym
unii-of1uit4rdh
of1uit4rdh ,
5-methylindolo[3,2-b]quinoline
nsc647765
5-methyl-5h-indolo[3,2-b]quinoline
C09142 ,
cryptolepine
480-26-2
ccris 9019
5h-quindoline, 5-methyl-
CHEMBL119096
chebi:3930 ,
bdbm50412201
cryptolepine hydrate
SCHEMBL542771
5-methylquindoline
KURWKDDWCJELSV-UHFFFAOYSA-N
DTXSID6037645
A936359
Q5190964
bdbm50589259

Research Excerpts

Overview

Cryptolepine hydrochloride is an indoloquinoline alkaloid isolated from the roots of Cryptolepis sanguinolenta. It has significant potential as an antiprotozoal and antibacterial.

ExcerptReferenceRelevance
"Cryptolepine (CRY) is a pharmacologically active plant alkaloid; it has significant potential as an antiprotozoal and antibacterial under different in vitro and in vivo conditions."( In vitro and in vivo growth inhibitory activities of cryptolepine hydrate against several Babesia species and Theileria equi.
Alkazmi, LM; Batiha, GE; Beshbishy, AM; Igarashi, I; Nadwa, EH; Rashwan, EK; Yokoyama, N, 2020
)
1.53
"Cryptolepine hydrochloride is an indoloquinoline alkaloid isolated from the roots of Cryptolepis sanguinolenta. "( The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells.
Angenot, L; Bailly, C; Bonjean, K; Colson, P; Dassonneville, L; De Pauw-Gillet, MC; Defresne, MP; Greimers, R; Houssier, C; Quetin-Leclercq, J; Tits, M; Wright, C, 1998
)
2.03
"Cryptolepine (1) is a rare example of a natural product whose synthesis was reported prior to its isolation from nature. "( Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta.
Bierer, DE; Cooper, R; Dubenko, LG; Fort, DM; Garofalo, AW; Gerber, RE; Imbach, PA; Litvak, J; Lu, Q; Luo, J; Phuan, PW; Reaven, GM; Sloan, B; Zhang, P, 1998
)
2.03

Effects

Cryptolepine has been shown to inhibit nitric oxide production, and DNA binding of Nuclear Factor-kappa B following inflammatory stimuli in vitro.

ExcerptReferenceRelevance
"Cryptolepine has been found to interact with either forms of DNA. "( Comparative binding studies on the interaction of the indoloquinoline alkaloid cryptolepine with the B and the non-canonical protonated form of DNA: A spectroscopic insight.
Bhuiya, S; Chowdhury, S; Das, S, 2021
)
2.29
"Cryptolepine has been shown to inhibit nitric oxide production, and DNA binding of Nuclear Factor-kappa B following inflammatory stimuli in vitro."( Anti-inflammatory properties of cryptolepine.
Ajayi, AM; Olajide, OA; Wright, CW, 2009
)
1.36

Treatment

ExcerptReferenceRelevance
"Cryptolepine-treated cells probably die via necrosis rather than via apoptosis."( Stimulation of topoisomerase II-mediated DNA cleavage by three DNA-intercalating plant alkaloids: cryptolepine, matadine, and serpentine.
Angenot, L; Bailly, C; Bonjean, K; Colson, P; Dassonneville, L; De Pauw-Gillet, MC; Houssier, C; Quetin-Leclercq, J, 1999
)
1.24

Toxicity

ExcerptReferenceRelevance
" With both P388 and HL-60 cells, cryptolepine proved about four times more toxic than its isomer."( Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis.
Bailly, C; Dassonneville, L; Lansiaux, A; Mahieu, C; Pieters, L; Van Miert, S; Wattelet, A; Wattez, N, 2000
)
0.83
" CSE at a high concentration (50 microg/ml) induced an apparent significant ten fold increase in mutant frequency compared to vehicle control (mean of 38 versus 4 mutant clones/10(6) surviving cells) but, this concentration of CSE was very toxic (<15% cell survival)."( In vitro genotoxicity of the West African anti-malarial herbal Cryptolepis sanguinolenta and its major alkaloid cryptolepine.
Ansah, C; Gooderham, NJ; Khan, A, 2005
)
0.54

Pharmacokinetics

cryptolepine showed a very high plasma clearance and volume of distribution (Vss) resulting in a moderate average plasma half-life of 4.

ExcerptReferenceRelevance
"7 h) elimination half-life compared to that of CHN (21."( Pharmacokinetics and in vivo chemosuppressive activity studies on cryptolepine hydrochloride and cryptolepine hydrochloride-loaded gelatine nanoformulation designed for parenteral administration for the treatment of malaria.
Addo, P; Al-Kassas, R; Kuntworbe, N; Ofori, M; Tingle, M, 2013
)
0.63
" Pharmacokinetic parameters of cryptolepine were determined in plasma and urine from Sprague Dawley rats after single-dose intravenous and oral administration."( Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats.
Amaral, A; Ansah, C; Cirello, A; Forkuo, AD; Gertsch, W; Pearson, D; Rynn, C; Spear, J; Wright, CW, 2017
)
1.07

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of cryptolepine alone and in combination with other antiplatelet agents have been investigated using a mouse model of arterial thrombosis."( Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis.
Okafor, JP; Oyekan, AO, 1989
)
1.02

Bioavailability

ExcerptReferenceRelevance
" Oral absorption was fast and plasma exposure and oral bioavailability were low."( Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats.
Amaral, A; Ansah, C; Cirello, A; Forkuo, AD; Gertsch, W; Pearson, D; Rynn, C; Spear, J; Wright, CW, 2017
)
0.79

Dosage Studied

ExcerptRelevanceReference
" The use of 20% ethanol as a dosage vehicle enhanced the protective effects of all drugs tested and the ethanol vehicle alone provided 45% protection."( Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis.
Okafor, JP; Oyekan, AO, 1989
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
cysteine protease inhibitorAny protease inhibitor that restricts the action of a cysteine protease.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organic heterotetracyclic compound
organonitrogen heterocyclic compoundAny organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
indole alkaloidAn alkaloid containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Telomerase reverse transcriptaseHomo sapiens (human)IC50 (µMol)9.40000.00062.69489.4000AID1850752; AID1858943; AID770979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-betaHomo sapiens (human)MIC0.25000.10003.450010.0000AID1858957
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
telomere maintenanceTelomerase reverse transcriptaseHomo sapiens (human)
RNA-templated transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
RNA-templated DNA biosynthetic processTelomerase reverse transcriptaseHomo sapiens (human)
telomere maintenance via telomeraseTelomerase reverse transcriptaseHomo sapiens (human)
mitochondrion organizationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of gene expressionTelomerase reverse transcriptaseHomo sapiens (human)
DNA strand elongationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of Wnt signaling pathwayTelomerase reverse transcriptaseHomo sapiens (human)
siRNA processingTelomerase reverse transcriptaseHomo sapiens (human)
regulation of protein stabilityTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of hair cycleTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of neuron apoptotic processTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of angiogenesisTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of glucose importTelomerase reverse transcriptaseHomo sapiens (human)
response to cadmium ionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityTelomerase reverse transcriptaseHomo sapiens (human)
establishment of protein localization to telomereTelomerase reverse transcriptaseHomo sapiens (human)
cellular response to hypoxiaTelomerase reverse transcriptaseHomo sapiens (human)
DNA biosynthetic processTelomerase reverse transcriptaseHomo sapiens (human)
replicative senescenceTelomerase reverse transcriptaseHomo sapiens (human)
siRNA transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of miRNA transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of transdifferentiationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of protein localization to nucleolusTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of endothelial cell apoptotic processTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of stem cell proliferationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of cellular senescenceTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTelomerase reverse transcriptaseHomo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
tRNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
transcription coactivator bindingTelomerase reverse transcriptaseHomo sapiens (human)
DNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
telomerase activityTelomerase reverse transcriptaseHomo sapiens (human)
telomerase RNA reverse transcriptase activityTelomerase reverse transcriptaseHomo sapiens (human)
RNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
RNA-directed DNA polymerase activityTelomerase reverse transcriptaseHomo sapiens (human)
RNA-dependent RNA polymerase activityTelomerase reverse transcriptaseHomo sapiens (human)
protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
identical protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
protein homodimerization activityTelomerase reverse transcriptaseHomo sapiens (human)
metal ion bindingTelomerase reverse transcriptaseHomo sapiens (human)
protein-folding chaperone bindingTelomerase reverse transcriptaseHomo sapiens (human)
telomerase RNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
template-free RNA nucleotidyltransferaseTelomerase reverse transcriptaseHomo sapiens (human)
telomeric DNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
PML bodyTelomerase reverse transcriptaseHomo sapiens (human)
chromosome, telomeric regionTelomerase reverse transcriptaseHomo sapiens (human)
nucleusTelomerase reverse transcriptaseHomo sapiens (human)
nucleoplasmTelomerase reverse transcriptaseHomo sapiens (human)
telomerase holoenzyme complexTelomerase reverse transcriptaseHomo sapiens (human)
nucleolusTelomerase reverse transcriptaseHomo sapiens (human)
cytosolTelomerase reverse transcriptaseHomo sapiens (human)
plasma membraneTelomerase reverse transcriptaseHomo sapiens (human)
nuclear speckTelomerase reverse transcriptaseHomo sapiens (human)
mitochondrial nucleoidTelomerase reverse transcriptaseHomo sapiens (human)
TERT-RMRP complexTelomerase reverse transcriptaseHomo sapiens (human)
telomerase catalytic core complexTelomerase reverse transcriptaseHomo sapiens (human)
nuclear telomere cap complexTelomerase reverse transcriptaseHomo sapiens (human)
RNA-directed RNA polymerase complexTelomerase reverse transcriptaseHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID551140Antifungal activity against Aspergillus fumigatus ATCC 90906 by CLSI method2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.
AID1054650Antimicrobial activity against Saccharomyces cerevisiae expressing ydj1 mutant gene assessed as sensitivity at 20 umol/L by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID284202Inhibition of p56/NFkappaB nuclear translocation in LPS-stimulated mouse RAW 264.7 cells administered at 10 uM for 30 mins after LPS challenge2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID284201Effect on IkappaB degradation in LPS-stimulated mouse RAW 264.7 cells administered at 10 uM for 30 mins after LPS challenge2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID550820Antifungal activity against Cryptococcus neoformans ATCC 90113 by microscopy2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID551139Antifungal activity against Candida krusei ATCC 6258 by CLSI method2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.
AID55326Inhibition of DNA interaction using DNA Methyl Green Assay.2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives.
AID1466363Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 24 hrs by liquid scintillation counting analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.
AID551138Antifungal activity against Candida albicans ATCC 90028 by CLSI method2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.
AID780197Antifungal activity against Cryptococcus neoformans ATCC 90113 by CLSI method2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
CoMFA studies and in vitro evaluation of some 3-substituted benzylthio quinolinium salts as anticryptococcal agents.
AID284200Effect on IkappaB phosphorylation in LPS-stimulated mouse RAW 264.7 cells administered at 10 uM for 30 mins after LPS challenge2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID1434054Antileishmanial activity against Leishmania donovani2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Antileishmanial evaluation of clubbed bis(indolyl)-pyridine derivatives: One-pot synthesis, in vitro biological evaluations and in silico ADME prediction.
AID402128Antimalarial activity as reduced parasitaemia against Plasmodium berghei infected Swiss albino mice (Mus musculus) at 50 mg/kg/day peroral dose for 4 days1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID88263Inhibition of beta-hematin formation; active2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives.
AID550817Antifungal activity against Candida albicans ATCC 90028 by microscopy2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID402127Antimalarial activity as reduced parasitaemia against Plasmodium berghei yoelii infected Swiss albino mice (Mus musculus) at 50 mg/kg/day peroral dose for 4 days1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID550818Fungicidal activity against Candida albicans ATCC 900282011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID1858953Antiproliferative activity against human A549 cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Jan-05, Volume: 227Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids.
AID402126Antiplasmodial activity against Plasmodium falciparum K1 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID550831Antifungal activity against Candida albicans ATCC 90028 at 20 ug/mL2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID492429Antimalarial activity against chloroquine-sensitive Plasmodium falciparum T9962009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
Antimalarials from nature.
AID1858934Antimalarial activity against Plasmodium berghei NK65 infected in Webster Swiss mouse assessed as parasite growth inhibition at 50 mg/kg/day, po for 5 days by geimsa dye based microscopy relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids.
AID1858956Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Jan-05, Volume: 227Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids.
AID1054644Antimicrobial activity against Saccharomyces cerevisiae expressing msh2 mutant gene assessed as increase in sensitivity measured as survival at 20 umol/L by spectrophotometry relative to wild type2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID551137Antifungal activity against Cryptococcus neoformans ATCC 90113 by CLSI method2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.
AID551141Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens.
AID1054672Antimicrobial activity against Aspergillus fumigatus ATCC 204305 by Alamar blue method2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID118219Mean body weight expressed as grams/mouse at 24hrs, when given at 100 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID780198Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red dye assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
CoMFA studies and in vitro evaluation of some 3-substituted benzylthio quinolinium salts as anticryptococcal agents.
AID1054673Antimicrobial activity against Cryptococcus neoformans ATCC 90113 by Alamar blue method2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID550822Antifungal activity against Aspergillus fumigatus ATCC 90906 assessed as inhibition of fungal growth by alamar blue assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID1054653Antimicrobial activity against Saccharomyces cerevisiae expressing snf2 mutant gene assessed as increase in sensitivity at 20 umol/L by spectrophotometry relative to wild type2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID105992Cytotoxicity against human diploid embryonic lung cell line MRC-5 using MTT assay2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives.
AID1054648Antimicrobial activity against Saccharomyces cerevisiae expressing rad52 mutant gene assessed as sensitivity at 50 umol/L by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID1872636Antibacterial activity against Mycobacterium fortuitum measured after 72 hrs by 96-well microtitre plate assay2022European journal of medicinal chemistry, Mar-15, Volume: 232Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation.
AID157843Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W22002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives.
AID1858957Inhibition of human topoisomerase-2-beta2022European journal of medicinal chemistry, Jan-05, Volume: 227Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids.
AID213823Antitrypanosomal activity against Trypanosoma cruzi; NT means not tested.2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives.
AID118218Mean body weight expressed as grams/mouse at 0hrs, when given at 100 mg/kg1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID1054671Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red dye assay2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID1054649Antimicrobial activity against wild type Saccharomyces cerevisiae assessed as sensitivity at 50 umol/L by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID1054668Selectivity index, ratio of TC50 for african green monkey Vero cells to MIC for Aspergillus fumigatus ATCC 2043052013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID1054674Antimicrobial activity against Candida albicans ATCC 90028 by Alamar blue method2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID380509Growth inhibition of Saccharomyces cerevisiae 1138 mutant by yeast bioassay1999Journal of natural products, Jul, Volume: 62, Issue:7
Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest.
AID284204Inhibition of DNA binding of NF-kappaB in LPS-stimulated mouse RAW 264.7 cells administered at 10 uM for 30 mins after LPS challenge by EMSA2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID1466364Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 after 24 hrs by liquid scintillation counting analysis2017European journal of medicinal chemistry, Jul-07, Volume: 134Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.
AID550821Fungicidal activity against Cryptococcus neoformans ATCC 901132011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID402124Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID284203Inhibition of DNA binding of NF-kappaB in LPS-stimulated mouse RAW 264.7 cells administered at 5 uM for 30 mins after LPS challenge by EMSA2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID3390In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID96364In vitro cell survival assay on cancer KB cell lines2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
New synthesis of benzo-delta-carbolines, cryptolepines, and their salts: in vitro cytotoxic, antiplasmodial, and antitrypanosomal activities of delta-carbolines, benzo-delta-carbolines, and cryptolepines.
AID284199Inhibition of NF-kappaB-mediated gene transcription in HEK293 cells by luciferase reporter gene assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID770979Inhibition of telomerase (unknown origin) by TRAP assay2013European journal of medicinal chemistry, Oct, Volume: 68Toward the design of new DNA G-quadruplex ligands through rational analysis of polymorphism and binding data.
AID113577Food intake in db/db Mice expressed as gram/mouse/day and the observation made is after 48 hr.1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
AID453260Inhibition of beta-hematin formation by BHIA assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID1054647Antimicrobial activity against Saccharomyces cerevisiae expressing msh2 mutant gene assessed as sensitivity at 50 umol/L by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID1054645Antimicrobial activity against Saccharomyces cerevisiae expressing ydj1 mutant gene assessed as sensitivity at 50 umol/L by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID1850752Inhibition of telomerase (unknown origin)2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Indoloquinolines as scaffolds for the design of potent G-quadruplex ligands.
AID1054646Antimicrobial activity against Saccharomyces cerevisiae expressing snf2 mutant gene assessed as sensitivity at 50 umol/L by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID213484Antitrypanosomal activity against Trypanosoma brucei.2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives.
AID1054655Antimicrobial activity against Saccharomyces cerevisiae expressing rad52 mutant gene assessed as increase in sensitivity at 20 umol/L by spectrophotometry relative to wild type2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID550816Antifungal activity against Candida albicans ATCC 90028 assessed as inhibition of fungal growth by alamar blue assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID1054651Antimicrobial activity against Saccharomyces cerevisiae expressing msh2 mutant gene assessed as sensitivity at 20 umol/L by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.
AID550834Cytotoxicity against african green monkey Vero cells2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID284198Cytotoxicity against mouse RAW 264.7 cells2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID284205Inhibition of DNA binding of NF-kappaB isolated from LPS-stimulated mouse RAW 264.7 cells administered at 250 uM after 30 mins by EMSA2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthetic cryptolepine inhibits DNA binding of NF-kappaB.
AID1858943Inhibition of telomerase (unknown origin)2022European journal of medicinal chemistry, Jan-05, Volume: 227Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids.
AID402125Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes by [3H]hypoxanthine uptake1997Journal of natural products, Jul, Volume: 60, Issue:7
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.
AID1850751Thermal stabilization of G4 quadruplex DNA (unknown origin) assessed as melting temperature by FRET method2022Bioorganic & medicinal chemistry letters, 09-15, Volume: 72Indoloquinolines as scaffolds for the design of potent G-quadruplex ligands.
AID157844Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum Ghana2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives.
AID453261Displacement of methyl green dye from DNA2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID3389In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (111)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (9.91)18.7374
1990's15 (13.51)18.2507
2000's32 (28.83)29.6817
2010's37 (33.33)24.3611
2020's16 (14.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.69 (24.57)
Research Supply Index4.75 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (30.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.88%)5.53%
Reviews8 (7.02%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other105 (92.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]